Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | +3.88% | +19.64% | +76.32% |
Mar. 21 | NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+75.44% | 53.99M | - | C | |
+3.30% | 108B | B+ | ||
+9.90% | 104B | B+ | ||
+6.49% | 23.66B | B | ||
-11.88% | 22.1B | B+ | ||
-3.29% | 19.71B | A- | ||
-35.36% | 18.2B | A- | ||
-13.21% | 16.19B | B | ||
+4.99% | 13.72B | C+ | ||
+34.75% | 12.22B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock NextCure, Inc. - Nasdaq
- Ratings NextCure, Inc.